Re: Non-prescription availability of low-dose codeine products
|
|
- Regina Moore
- 5 years ago
- Views:
Transcription
1 2017 November 7 Michelle Boudreau Director General Legislative and Regulatory Affairs Controlled Substances Directorate Healthy Environments and Consumer Safety Branch Health Canada Address Locator: 0302A 150 Tunney s Pasture Driveway Ottawa, Ontario K1A 0K9 ocs_regulatorypolicy-bsc_politiquereglementaire@hc-sc.gc.ca. Re: Non-prescription availability of low-dose codeine products Dear Ms. Boudreau, Thank you for the opportunity to provide feedback regarding the proposed changes to the regulations to the Controlled Drugs and Substances Act requiring all products containing codeine to be sold by prescription only. Members of the Canadian Society of Hospital Pharmacists (CSHP) were invited to provide comments on the proposal. I am pleased to share the comments received, in summary and detailed form. (The details are provided as an attachment.) Patient safety is paramount. Non-prescription access to low-dose codeine products can increase the risk exposure to patients. The opportunity to selfmedicate (regardless of whether the product contains codeine) without routine follow-up places patients at a higher risk of preventable adverse drug reactions. The risks associated with low-dose codeine products could be better managed if they are available only by prescription. And so, there is agreement among members who responded that additional restrictions on the sale of codeine products are needed. Some members want codeine products to be available only by prescription, while others want a further step to be taken: remove codeine products from the market. It was suggested that information be obtained from the provincial poison centres to help evaluate the risk-versus-benefit profile of codeine-containing preparations. The opioid crisis is a system-wide problem. A move to prescription-only status for codeine products will not fix the current situation, but it stands to
2 help. The following anticipated unintended, undesirable consequences were mentioned: o A shift to other (potentially more potent, expensive, or illicit) opioids o A shift to non-prescription analgesics that could be harmful to the patient (and are available without the intervention of a pharmacist) o Increased burden in the healthcare system (arising from an increase in appointments with practitioners authorized to prescribe a codeinecontaining product), possibly causing delays in accessing required medication Changes made to the Act regarding the sale of codeine products should reflect what has been learned about the effectiveness of efforts to curb the sale of codeine preparations in other countries and Canadian provinces. Continued dialogue with healthcare professionals was requested. If you have any questions about the information provided herein, please do not hesitate to contact me at , or via at clyder@cshp.ca. Sincerely, Cathy Lyder Director, Members and Programs Cc Patrick Fitch, CSHP President Douglas Doucette, CSHP President Elect and External Liaison Myrella Roy, CSHP Executive Director
3 Consultation on non-prescription availability of lowdose codeine products I think all codeine products and doses should require a physician s prescription. I agree that we need to address the opioid (fentanyl) crisis. But removing an abused substance from the market place will not stop the problem. It just redirects it to another area. We have created the current fentanyl crisis by removing oxycodone from the provincial formularies. We didn t offer all the people using oxycodone rehab therapy and as a result they filled the void we created. Switching codeine products to prescription status will not fix the opioid crisis and may possibly have an unintended consequence. Please urge government and Health Canada to sit down with front line health care practitioners before making any decisions. I am fully supportive of Health Canada changing the regulatory status of codeine to only be available via prescription. This proposed change is in the best interest of patient safety. As a practising pharmacist, I am aptly positioned to comment on this important regulatory change. I have practiced both in community and hospital settings. As a community pharmacist, it can be difficult to identify individuals who may potentially abuse codeine products. From my experience, many patients know how to work the system by accurately answering the questions regarding appropriate use. As well, as a healthcare professional you do not want to deny any patient access to a therapy that they may require for a legitimate reason (e.g., pain control for an acute injury), and many patients that abuse codeine can be very convincing. In my province, we do not have a mechanism to track the sale of codeine products. Thus, it is impossible to know if a patient is buying multiple codeine products by going from pharmacy-to-pharmacy. Another scenario I have encountered was a patient with complex chronic pain who was self-prescribing over-the-counter combination codeine-acetaminophen products. Every time she made a purchase, we discussed at length the appropriate use of codeine-acetaminophen, and availability of more effective/less toxic alternatives via prescription. However, she did not have a regular primary care provider, and it was much easier for her to purchase codeine over-the-counter. We
4 tracked her usage and tried to limit her use, but she still ended up with an acute liver injury from acetaminophen because she escalated her dose on her own. I still remember this patient vividly I tried to do everything in my power to prevent her from harming herself, but was ultimately unsuccessful. I acknowledge this incident may not have been prevented if codeine was only available via prescription, but it would at least have forced her to access a primary care provider (even at a walk-in clinic), and she may have been stabilized on a safer chronic therapy. Finally, in my pharmacy practice I have a great deal of experience providing consultative pharmacy services for patients with chronic pain on opioid therapy including the provision of take home naloxone kits. There are numerous patients with opioid misuse disorder at the clinic, and the number of opioid-related overdose deaths in this province continues to rise at an alarming rate. Therefore, if we can prevent even a small number of patients from developing opioid misuse disorder by limiting access to codeine, this regulatory change will be worthwhile. First of all, I applaud Health Canada for proposing restrictions of sales to these products. I would suggest going one step further, and eliminating them all together. I am very proud to say we have successfully removed all codeine-containing products from our hospital formularies at our adult and pediatric hospitals. Codeine as an analgesic: Codeine is a weak opioid with 200-fold less affinity for the mu-opioid receptor compared with morphine. Codeine is considered to be a prodrug and the analgesic properties of codeine are attributed to its conversion to morphine and morphine-6-glucuronide via a minor metabolic pathway. The transformation to morphine occurs via CYP2D6, a genetically highly polymorphic drug metabolizing enzyme that is subject to marked inter-individual variability in the amount of morphine produced. The administration of codeine is essentially equivalent to the administration of and UNKNOWN dose of morphine. My comments: codeine should NOT be licensed for sale in Canada as an analgesic. Codeine for suppressing cough: Codeine is widely regarded as the gold standard cough suppressant drug however, very few studies have investigated the antitussive efficacy of codeine. My comments: codeine as a cough suppressant lacks good data to support this claim. Codeine and patient harm: Patient harm from codeine can occur via its lack of metabolism to morphine (i.e., lack of efficacy) or via its metabolism to morphine (as
5 an opioid agonist). In addition many of the products were also combined with a fixed dose of acetaminophen (liver toxicity). I would encourage Health Canada to obtain some statistics on exposures to these products from the 5 provincial Poison Centres (if they have not already done this). In my opinion this type of data is essential in order to evaluate the risk vs benefit of these formulation to the Canadian population. My comments: low-dose codeine products are more likely to cause patient harm than patient benefit. They should NOT be licensed for sale in Canada. Concerns regarding patient accessing health care systems for products they would otherwise have accessed without the intervention of a prescriber: Healthcare providers should welcome this potential intervention. The move to prescription-only access for low-dose codeine products is welcome as a first step. However, I would prefer the complete removal of codeine from the market. Given the availability and greater pharmacological predictability of morphine over codeine, codeine is not needed. Such changes would come with unintended, undesirable consequences which would need to be managed. There would likely be an increase in the number of visits to obtain a prescription from a practitioner who is authorized to prescribe those products. While that is not necessarily undesirable, the system is not sufficiently resourced to handle the increased demand in a timely manner. Pharmacists currently have a role in the sale of low-dose codeine products and an expansion of their role to include prescribing of controlled substances should not be overlooked. There could be higher migration from low-dose codeine products to illicit drugs or to higher doses of codeine-containing products that are currently available only with a prescription. (Overtime the usage of low-dose codeine will likely decline significantly.) For many reasons (e.g., avoiding the time for a medical appointment), patients may choose to self-medicate with either an illicit drug, someone else s analgesic, or with a non-prescription drug whose use is approved in Canada but contraindicated for the patient s condition. The incidence of doctor-shopping or double-doctoring will likely not decline, and stands to increase.
6 The information in the Gazette refers to countries and Canadian provinces that have restricted access to low-dose codeine products, but does not describe the outcome of such changes. It would be helpful to healthcare professionals to know the experiences and outcome the changes in those areas.
RE: PROPOSED AMENDMENTS TO REGULATIONS TO THE CONTROLLED DRUGS AND SUBSTANCES ACT
November 8, 2017 Ms. Michelle Boudreau Director General Controlled Substances Directorate Office of Legislative and Regulatory Affairs Health Canada 150 Tunney s Pasture Driveway, Main Stats Building Address
More informationJanuary 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9
January 19, 2018 Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9 By email: cannabis@canada.ca RE: Proposed Approach to the Regulation of Cannabis
More informationReview of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
More informationAppearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse
Opening Statement Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Dr. Chris Simpson, President-elect
More informationOCSA HEALTH CANADA NOTICE OF INTENT - Vape Products
March 19, 2019 Manager Regulation Division, Tobacco Products Regulatory Office Tobacco Control Directorate, Controlled Substances and Cannabis Branch Health Canada 0301A, 150 Tunneys Pasture Driveway,
More informationOctober 15, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. FDA-2012-N-0548 To Whom It May Concern: The American Dental Association
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D SIXTY-FIRST REGULAR SESSION April 24-26, 2017 Washington, D.C. OEA/Ser.L/XIV.2.61 CICAD/doc.2299/17 21 April 2017 Original: English CANADA S OPIOID
More informationCommunity Pharmacy Distribution of Naloxone
Community Pharmacy Distribution of Naloxone College of Pharmacists of BC BC Centre for Disease Control Harm Reduction Program Sponsored in part by the BC Ministry of Health What is Naloxone? Naloxone is
More informationFrequently Asked Questions
Page 1 Frequently Asked Questions Codeine and all multiple-ingredient products containing codeine are restricted on the AHS Provincial Drug Formulary to patients 18 years of age and older. 1. What does
More informationWhat is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls?
What is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls? What is an opioid? What do opioids do?: The term opioid can be
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D SIXTY-THIRD REGULAR SESSION April 25-27, 2018 México D.F., México OEA/Ser.L/XIV.2.63 CICAD/doc.2385/18 25 April 2018 Original: English THE OPIOID
More informationNon-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients
Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationOpioids Are Seniors at Risk? (April 26, 2018)
Opioids Are Seniors at Risk? (April 26, 2018) Seniors are living longer and, with age, they become vulnerable to health challenges and the pain that may accompany them. Thus, it is perhaps not surprising
More informationPatient and Family Agreement on Opioids
Patient and Family Agreement on Opioids We care about our patients and are committed to their recovery and wellness. We offer our patients medications and options for various services to keep them from
More informationONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE. Dr. David Williams Chief Medical Officer of Health
ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE Dr. David Williams Chief Medical Officer of Health National opioid-related mortality data, 2016 (Health Canada) Provincial Overdose Coordinator
More informationFood and Drug Regulations - Project Number Schedule F
Graham Spry Building 250 Lanark Avenue Address Locator: 2005D Ottawa, Ontario K1A 0K9 09-128254-482 Provincial and Territorial Deputy Ministers of Health Provincial and Territorial Drug Program Managers
More informationLocation of initiative York Region Chronic Kidney Disease Program, Mackenzie Richmond Hill Hospital, Richmond Hill, ON
Story # CSHP 015 objective Objective.1 - In 70% of ambulatory and specialized care clinics providing clinic care, pharmacists will manage medication therapy for clinic patients with complex and high-risk
More informationOpioid Pain Medications Frequently Asked Questions
Opioid Pain Medications IT S YOUR HEALTH Opioid Pain Medications What is an opioid? Opioids are a broad range of natural and manufactured (synthetic) compounds that are commonly used for pain relief. There
More informationPharmaceutical Misuse and its Challenges: Opioid Use in Ontario. Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012
Pharmaceutical Misuse and its Challenges: Opioid Use in Ontario Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012 Objectives To review the prescription opioid crisis To understand the
More informationNALOXONE RISK ASSESSMENT
NALOXONE RISK ASSESSMENT Intended audience: Non-public sector organizations. Introduction: BC is currently experiencing a public health emergency related to the unprecedented increase in opioid overdoses
More informationOpioid Harm Reduction
Opioid Harm Reduction Lucas G. Hill, PharmD Clinical Assistant Professor, The University of Texas at Austin College of Pharmacy Clinical Pharmacist, CommUnityCare FQHCs Director, Operation Naloxone Mark
More informationCMA Response: Health Canada s Medical Marihuana Regulatory Proposal. Submitted to the Office of Controlled Substances Health Canada.
CMA Response: Health Canada s Medical Marihuana Regulatory Proposal Submitted to the Office of Controlled Substances Health Canada February 28, 2013 A healthy population and a vibrant medical profession
More informationFrom Wikipedia, the free encyclopedia
1 of 6 11/24/2010 11:43 PM From Wikipedia, the free encyclopedia The regulation of therapeutic goods, that is drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United
More informationRe: Bill 33, Safeguarding our Communities Act (Fentanyl Patch for Patch Return Policy), 2015
November 30, 2015 Mr. Peter Tabuns Chair, Standing Committee on Social Policy 99 Wellesley Street West, Room 1405 Whitney Block Queen's Park Toronto, ON M7A 1A2 Dear Mr. Tabuns: Re: Bill 33, Safeguarding
More informationJuly 6, Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration New Hampshire Avenue Silver Spring, MD 20993
Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Draft Revisions to the Food and Drug Administration Blueprint for Prescriber Education
More informationManaged Care Pushes for Safer Opioid Oversight
Page 1 of 6 Clinical AUGUST 11, 2017 Managed Care Pushes for Safer Opioid Oversight High-risk pain Rx eyed Denver Health systems haven t escaped the nation s ongoing opioid crisis, as evidenced by surging
More informationOpioid Analgesics: Responsible Prescribing in the Midst of an Epidemic
Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Lucas Buffaloe, MD Associate Professor of Clinical Family and Community Medicine University of Missouri Health Care Goals for today
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More information1) Louisiana s Opioid Addiction 2) Adopting a Drug Formulary - HB 592 3) What is the ODG Drug Formulary and How is it Used in Workers Comp 4) The
1) Louisiana s Opioid Addiction 2) Adopting a Drug Formulary - HB 592 3) What is the ODG Drug Formulary and How is it Used in Workers Comp 4) The Role of Diagnosis (how it will work with the current treatment
More informationCannabis for Medical Purposes
College of Physicians and Surgeons of British Columbia Cannabis for Medical Purposes Preamble This document is a standard of the Board of the College of Physicians and Surgeons of British Columbia. College
More informationMinister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018
The Minister s Opioid Emergency Response Commission was established May 31, 2017 to support the Government of Alberta s urgent response to the opioid crisis. As part of its mandate, the Commission is responsible
More informationWR Fentanyl Symposium. Opioids, Overdose, and Fentanyls
Opioids, Overdose, and Fentanyls Outline: What are opioids? Why are we experiencing and opioid crisis? Potency, purity, and product How do opioids cause overdose and overdose deaths? What is naloxone and
More informationHealth Canada s Proposed Approach to Managing Caffeinated Energy Drinks
Health Canada s Proposed Approach to Managing Caffeinated Energy Drinks October 2011 Food Directorate, Health Products and Food Branch 1 Table of Contents Background... 3 Assessment of the Potential Health
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationIncrease in Opioid Related Deaths What the Data Can Tell us. Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes
Increase in Opioid Related Deaths What the Data Can Tell us Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes Objectives Prescription Opioid Misuse and Abuse: How did we get here? Opioid
More informationOPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN
OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN ANTOINETTE BROWN, RPH LAUREL RAMER, 2019 PHARMD CANDIDATE 2018 WYOMING CONFERENCE ON AGING LARAMIE, WY OCTOBER 3, 2018 OBJECTIVES 1. Understand the
More informationOpioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
More informationFentanyl, Opioid Overdose and Naloxone
Fentanyl, Opioid Overdose and Naloxone Opioid Agonist Therapy Conference Saskatoon, SK April, 2016 Declaration No conflict of interest. Consultant in Addiction Medicine, SHR. Chair, College of Physicians
More informationCare not Corrections SUMMARY REPORT APRIL Relieving the Opioid Crisis in Canada CANADIAN MENTAL HEALTH ASSOCIATION
Care not Corrections Relieving the Opioid Crisis in Canada CANADIAN MENTAL HEALTH ASSOCIATION SUMMARY REPORT APRIL 2018 SUMMARY REPORT Canada is confronting an unprecedented public health crisis. In 2016-2017,
More informationPresentation to the Standing Committee on Health on Bill C-206, an Act to Amend the Food and Drugs Act
Check against delivery Presentation to the Standing Committee on Health on Bill C-206, an Act to Amend the Food and Drugs Act Michel Perron, CEO The Canadian Centre on Substance Abuse March 21, 2005 I
More informationSUBSTANCE USE GUIDELINES
SUBSTANCE USE GUIDELINES Approved by: Academic Coordinating Committee Authorizer: Vice President, Finance and Corporate Services Reference Code: OHSS28 V1 Effective Date: 10/17/2018 PURPOSE The purpose
More informationAttitudes Toward Medication-Assisted Treatment Within a Drug Court Program. Caroline Allison. Dr. Kathleen Moore, Ph.D.
Running Head: MEDICATION-ASSISTED TREATMENT ATTITUDES Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program Caroline Allison Dr. Kathleen Moore, Ph.D. Department of Mental Health Law
More informationOntario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
More informationOpioid Overdose in Oregon Report to the Legislature
SEPTEMBER 2018 Opioid Overdose in Oregon Report to the Legislature This report summarizes the burden of opioid overdose among Oregonians as required by ORS 432.141. It describes Oregon s progress in reducing
More informationOpioid Prescribing for Acute Pain
Patient Reference Guide Opioid Prescribing for Acute Pain Care for People 15 Years of Age and Older Quality standards outline what high-quality care looks like. They focus on conditions or topics where
More informationFDA s Response to the Opioid Crisis and the FDA Safe Use Initiative
FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.
More informationREAL TIME MONITORING OF PRESCRIPTION MEDICINES BEING A HEALTHY STATE
BEING A HEALTHY STATE 2036 WILL MARK OUR STATE S BICENTENARY By the time our State turns 200 years old, I want South Australia to be a place of prosperity. Planning and delivering on my vision for a better
More information3.0 Approval of the minutes March 6, 2011 The minutes were approved as circulated electronically to Committee members and posted on the NAPRA website.
A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on Sunday, September 11 and Monday September 12, 2011, at the Lord Elgin Hotel, Ottawa. Participants Committee members Dr.
More informationHydrocodone compound cough syrup. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Hydrocodone compound cough syrup Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Free online pharmacy compare service for consumers with many brand and generic
More informationD. Todd Bess, PharmD 1
s Program as a Tool to Improve Patient Care and Fight the Drug Epidemic D. Todd Bess, Pharm.D. Director April 12, 2018 Disclosure Information I have no financial relationships to disclose. I will not discuss
More information6/6/2017. First Do No Harm SECTION 1 THE OPIOID CRISIS. Implementing an Opioid Stewardship Program in a HealthCare System OBJECTIVES
First Do No Harm Implementing an Opioid Stewardship Program in a HealthCare System Phil Chang, MD Kristy Deep, MD Doug Oyler, PharmD June 12, 2017 OBJECTIVES Explain the role of opioid stewardship as a
More informationRE: CONSULTATION ON DRAFT - DRUG AND NATURAL HEALTH PRODUCTS RECALL GUIDE
January 14, 2019 Health Products Compliance and Enforcement Unit Regulatory Operations and Regions Branch Health Canada By email to: hc.hpce-cpsal.sc@canada.ca RE: CONSULTATION ON DRAFT - DRUG AND NATURAL
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationStandard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)
Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care) Preamble This Standard establishes the standards of practice and ethical requirements of all physicians
More information9/13/2017 DEA WHO WE ARE: Prescription Drug Abuse. American Association of Service Coordinators September 24-27, 2017 Disney s Coronado Springs Resort
DEA FIELD OFFICES IN FLORIDA Miami Divisional Office David Wickey, GS 954-306-4650 Orlando District Office Linda Stocum, GS 407-333-7046 Tampa District Office Amie Hickerson, GS 813-287-5160 Tallahassee/Jacksonville
More informationGetting the best from the medicines you buy
Getting the best from the medicines you buy You can buy many medicines without needing to see your doctor. These are often called over-the-counter medicines. They are safe and effective as long as you
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationHydrocodone Combination Analgesic Products Clinical Impact of a Schedule Change
Hydrocodone Combination Analgesic Products Clinical Impact of a Schedule Change Frederick A. Curro D.M.D., Ph.D. Director, PEARL Practice Based Research Network Director, Regulatory Affairs, Bluestone
More informationUnderstanding the Opiate Epidemic
Understanding the Opiate Epidemic An opiate is a narcotic analgesic that depresses the central nervous system. Natural opiates are derived from the poppy plant. Synthetic opiates are manufactured drugs
More informationNaloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program
Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program Andrea Leonard-Segal, M.D., M.S. Director, Division of Nonprescription Clinical Evaluation 1 Contents
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Analgesics, Narcotic Long Acting A. Prescriptions That Require Prior Authorization Prescriptions for Analgesics, Narcotic Long Acting
More informationOpioid epidemic and PEHP
Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe
More informationThe 86 th Texas Legislature s Policy Response to Opioids Prepared by the Texas Orthopaedic Association
The 86 th Texas Legislature s Policy Response to Opioids Prepared by the Texas Orthopaedic Association The United States is in the midst of an epidemic of substance misuse and abuse that applies to all
More informationSection I. Short-acting opioid Prior Authorization Criteria
Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization
More informationAUDITOR GENERAL S REPORT
AUDITOR GENERAL S REPORT Supplementary Report to the Auditor General's Phase One Report: "The City Needs to Ensure Adequate Detection and Review of Potentially Excessive and Unusual Drug Claims" June 13,
More information6/6/2017. Faculty/Presenter Disclosure. Disclosure of Commercial Support
Opioids in Ontario, Canada: The need to reduce the prescribed opioid load; and need for mass casualty preparation Kieran Moore, Professor of Emergency Medicine, Queen s University, Associate Medical Officer
More informationThe Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017
The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017 The Mississippi Drug Abuse Project, Mississippi State Department of Health Working Group Manuela Staneva, MPH, Project Epidemiologist Meg
More informationOpioids - Fentanyl - Naloxone. Public Health Nurse
Opioids - Fentanyl - Naloxone Public Health Nurse What are Opioids? Opioids are a family of drugs that treat pain and can cause sleepiness. Prescription (legal) Opioids fall into 3 main categories: 1.
More informationMichael M. Miller, MD, FASAM, FAPA
Michael M. Miller, MD, FASAM, FAPA mmiller@rogershospital.org Medical Director, Herrington Recovery Center (HRC) Rogers Memorial Hospital Oconomowoc, Wisconsin Vice Speaker Wisconsin Medical Society Clinical
More informationExpert Peer Review for Carfentanil
Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6-10 November 2017 Expert Peer Review for Carfentanil 1. Comments based on the review report a. Evidence on dependence and abuse potential
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationHarm Reduction Program Enhancement Questions and Answers. Population and Public Health Division Ministry of Health and Long-Term Care
Harm Reduction Program Enhancement Questions and Answers Population and Public Health Division Ministry of Health and Long-Term Care Table of Contents General Questions... 3 Funding... 4 Local Opioid Response...
More informationMedicare Advantage Outreach and Education Bulletin
Medicare Advantage Outreach and Education Bulletin Blue Cross and Blue Shield of Georgia Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain
More information2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC Washington, DC 20515
The Honorable Greg Walden Chairman Ranking Member 2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC 20515 Washington, DC 20515 Chairman Ranking Member Subcommittee on
More informationScript for audio: Pseudoephedrine and ephedrine. Audiovisual training for pharmacy support staff
Script for audio: Pseudoephedrine and ephedrine Audiovisual training for pharmacy support staff The aim of this presentation is to provide you with information about the changes that are taking place to
More informationThe Opioid Epidemic: The State of the State
JOINT LEGISLATIVE COMMITTEE ON HEALTH AND HUMAN SERVICES The Opioid Epidemic: The State of the State Dr. Mandy Cohen, Dr. Susan Kansagra Department of Health and Human Services Nov. 14, 2017 3 PEOPLE DIE
More informationWILLIAMS, WYCKOFF & OSTRANDER, PLLC Attorneys at Law
WILLIAMS, WYCKOFF & OSTRANDER, PLLC Attorneys at Law Wayne L. Williams Douglas P. Wyckoff Dane D. Ostrander 2958 Limited Lane N.W. P O Box 316 Olympia, WA 98507 Telephone (360) 528-4800 Telefax (360) 943-2430
More informationOHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS
OHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS DEFINITIONS Opiate- originate from naturally-occurring elements found in the opium poppy plant. These drugs are
More informationTITLE NALOXONE STATEWIDE STANDING ORDER UPDATE & NARCAN ACCESS ONE-DAY EVENT
TITLE NALOXONE STATEWIDE STANDING ORDER UPDATE & NARCAN ACCESS ONE-DAY EVENT WELCOME Kate Gainer, PharmD Executive Vice President and CEO Iowa Pharmacy Association PRESENTER Kevin Gabbert, LISW, IAADC
More informationPublic Health Association of British Columbia
October 30 th, 2017 Open Letter to the Government of British Columbia: BC Needs an OPIOID ACTION PLAN Since April, 2016 when the epidemic of opioid overdose deaths was declared a Public Health Emergency
More informationWhat is drug diversion?
Learning Objectives Identify the impact of drug diversion on patients and healthcare organizations Explain the common points of risks and methods of drug diversion in healthcare s controlled substance
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationRecommendations for Components of Emergency Department Discharge Protocols
Recommendations for Components of Emergency Department Discharge Protocols Background Maryland, like many other states, is in the midst of an opioid crisis. In 2016, 89 percent of all intoxication deaths
More informationI am pleased to highlight for this Honourable House and the public. that today the Government will be laying amendments to the
MINISTERIAL STATEMENT TO THE HOUSE OF ASSEMBLY BY THE HONOURABLE KIM N. WILSON, JP, MP MINISTER OF HEALTH UPDATES AND MODERNIZATION OF DRUG SCHEDULES 24 November 2017 Mr Speaker and Honourable Members,
More informationResponse to request for submissions regarding regulation of non-medical cannabis
Suite 840-605 Robson Street Vancouver, BC V6B 5J3 www.cnpbc.bc.ca November 1, 2017 Ministry of Public Safety and Solicitor General PO Box 9285 Stn Prov Govt Victoria, BC V8W 9J7 BY EMAIL ONLY: cannabis.secretariat@gov.bc.ca
More informationNaloxone and Combating the Opioid Epidemic
Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to
More informationTake Home Naloxone elearning Module Script
elearning Module Script Slide 1-3 Review the outline and the plan for the presentation. Slide 4 We do accept the cynicism of this poster. Slide 5 Read from the slide the definition of Harm Reduction Slide
More informationThe Population is Abusing Drugs, but are Drugs Abusing Insurance?
Image licensed from Shutterstock The Population is Abusing Drugs, but are Drugs Abusing Insurance? 01/30/2018 Gina C. Guzman, MD, DBIM, FALU, FLMI, VP and Chief Medical Director Tim Morant, FSA, MAAA,
More informationAcademic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationDISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.
DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: April 21, 2017 Purpose The intent of this document is to provide
More informationPrescription Drug Monitoring Programs and Other State-Level Strategies
Prescription Drug Monitoring Programs and Other State-Level Strategies Interventions to Reduce Opioid-Related Harms: Misuse, Abuse, Addiction, and Overdose Tamara M. Haegerich, PhD Acting Associate Director
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationService Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian
Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian 1. Introduction The provision of Substance Misuse (SM) services through
More informationMedicines Optimisation Strategy
Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic
More informationYukon s Proposed Framework for. Legalized Cannabis 30 GRAMS MINIMUM AGE
Yukon s Proposed Framework for Legalized Cannabis 30 GRAMS x4 MINIMUM AGE Overview The Government of Yukon has begun developing a new act to regulate cannabis in response to federal legislation planned
More informationAppropriate prescribing of Oxycodone for non-cancer pain in general practice
CLINICAL AUDIT Appropriate prescribing of Oxycodone for non-cancer pain in general practice Valid to October 2022 bpac nz better medicin e Background Oxycodone is a strong opioid that milligram for milligram
More informationSpotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017
Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial
More informationNaloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no
THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any
More information